RenalGuard Solutions, Inc., accessible at renalguard.com, operates in the medical technology sector, focusing on innovative solutions to prevent and manage acute kidney injuries (AKI) and heart failure symptoms. The company primarily serves healthcare providers, including hospitals and clinics, that perform image-guided cardiology and radiology procedures, as well as those treating patients with acute decompensated heart failure (ADHF).

RenalGuard's flagship product, RenalGuard Therapy, is designed to protect patients from procedure-induced acute kidney injury (AKI). AKI can occur in up to 30% of patients undergoing cardiac surgery and is a significant predictor of both morbidity (illness) and mortality (death). The technology was initially developed to mitigate the harmful effects of contrast media—a dye used in imaging procedures—on the kidneys, a condition known as Contrast-Induced Nephropathy (CIN). Two European studies have shown RenalGuard's effectiveness in preventing CIN.

Additionally, RenalGuard offers Reprieve Guided Diuretic Therapy, which helps manage fluid levels in patients undergoing diuretic therapy for ADHF. This therapy aims to alleviate symptoms associated with heart failure by optimizing fluid removal from the body, thereby reducing congestion and improving patient outcomes.

RenalGuard operates on a business-to-business (B2B) model, selling its technology and related services directly to healthcare institutions. The company generates revenue through the sale of its medical devices and ongoing support services, which include training and maintenance.

In summary, RenalGuard Solutions, Inc. is a specialized medical technology company dedicated to improving patient outcomes in cardiology and nephrology through innovative fluid management solutions.

Keywords: Acute Kidney Injury, Contrast-Induced Nephropathy, Heart Failure, Fluid Management, Medical Technology, Cardiology, Radiology, Diuretic Therapy, Patient Safety, Healthcare Providers.